Avidity Biosciences (RNA) Competitors

Avidity Biosciences (NASDAQ:RNA) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Is RNA or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Avidity Biosciences' net margin of -4,247.77%. Genmab A/S's return on equity of 21.03% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-4,247.77%	-33.45%	-30.22%
Genmab A/S	37.53%	21.03%	16.98%

Do analysts prefer RNA or GMAB?

Avidity Biosciences presently has a consensus price target of $67.00, suggesting a potential upside of 45.43%. Genmab A/S has a consensus price target of $37.80, suggesting a potential upside of 64.49%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Avidity Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	0 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.06
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Which has more volatility and risk, RNA or GMAB?

Avidity Biosciences has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Does the media prefer RNA or GMAB?

In the previous week, Avidity Biosciences had 9 more articles in the media than Genmab A/S. MarketBeat recorded 27 mentions for Avidity Biosciences and 18 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.93 beat Avidity Biosciences' score of 0.54 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	10 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of RNA or GMAB?

7.1% of Genmab A/S shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has better valuation and earnings, RNA or GMAB?

Genmab A/S has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$10.90M	543.75	-$322.30M	-$3.00	-15.36
Genmab A/S	$3.12B	4.72	$1.14B	$1.99	11.55

Summary

Genmab A/S beats Avidity Biosciences on 10 of the 15 factors compared between the two stocks.